Innate Pharma S.A. (IPHA)

Market Cap	149.94M -22.0%
Revenue (ttm)	14.84M -62.6%
Net Income	-54.08M
EPS	-0.64
Shares Out	92.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,523
Open	1.600
Previous Close	1.600
Day's Range	1.570 - 1.660
52-Week Range	1.460 - 2.630
Beta	0.57
Analysts	Strong Buy
Price Target	5.00 (+209.6%)
Earnings Date	Mar 26, 2026

About IPHA

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 17, 2019
• Employees: 174
• Stock Exchange: NASDAQ
• Ticker Symbol: IPHA
• Website: https://www.innate-pharma.com

Financial Performance

In 2024, Innate Pharma's revenue was 20.12 million, a decrease of -67.36% compared to the previous year's 61.64 million. Losses were -49.47 million, 553.5% more than in 2023.

Financial numbers in EUR

Analyst Summary

According to 3 analysts, the average rating for IPHA stock is "Strong Buy." The 12-month stock price target is $5.0, which is an increase of 209.60% from the latest price.

Price Target

$5.0

(209.60% upside)

Analyst Consensus: Strong Buy